Sclerotherapy (STS) vs sclerotherapy (any sclerosant)
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
- no estimate extracted4 studies · 473 participantsModerate
Sclerotherapy (STS) probably leads to higher adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
Sclerotherapy (STS) probably leads to higher adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
Sclerotherapy (STS) showed no clear difference in pain ( compared with sclerotherapy (any sclerosant) (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.